As the incidence of neuroendocrine tumors has been rising, gender differences in epidemiology and clinical behavior have emerged, and interest into a gender-driven management of these tumors has grown with the aim to improve survival and quality of life of these patients. Somatostatin Analogues represent the first line of systemic treatment of both functional and non-functional neuroendocrine tumors, through the expression of somatostatin receptors (SSTRs) in the tumor cells, and proved effective in controlling hormonal hypersecretion and inhibiting tumor growth, improving progression-free survival and overall survival of these patients. Aim of the present review is to investigate any differences by gender in efficacy and safety of SSTS-targeted therapies, that represent the mainstay treatment of neuroendocrine tumors, as they emerge from studies of varying design and intent. Although preclinical studies have provided evidence in favor of differences by gender in tumor expression of SSTR, as well as of the role of sex hormones and related receptors in modulating SSTRs expression and function, the clinical studies conducted so far have not shown substantial differences between males and females in either efficacy or toxicity of SSTR-targeted therapies, even if with sometimes inconsistent results. Moreover, in most studies gender was not a predictor of response to treatment. Studies specifically designed to address this issue are needed to develop gender-specific therapeutic algorithms, improving patients' prognosis and quality of life.

Efficacy and tolerability of somatostatin analogues according to gender in patients with neuroendocrine tumors / Ruggeri, Rosaria M; Aini, Irene; Gay, Stefano; Grossrubatscher, Erika Maria; Mancini, Camilla; Tarsitano, Maria Grazia; Zamponi, Virginia; Isidori, Andrea M; Colao, Annamaria; Faggiano, Antongiulio. - In: REVIEWS IN ENDOCRINE & METABOLIC DISORDERS. - ISSN 1389-9155. - (2023), pp. 1-16. [10.1007/s11154-023-09858-6]

Efficacy and tolerability of somatostatin analogues according to gender in patients with neuroendocrine tumors

Gay, Stefano;Mancini, Camilla;Tarsitano, Maria Grazia;Zamponi, Virginia;Isidori, Andrea M;Faggiano, Antongiulio
2023

Abstract

As the incidence of neuroendocrine tumors has been rising, gender differences in epidemiology and clinical behavior have emerged, and interest into a gender-driven management of these tumors has grown with the aim to improve survival and quality of life of these patients. Somatostatin Analogues represent the first line of systemic treatment of both functional and non-functional neuroendocrine tumors, through the expression of somatostatin receptors (SSTRs) in the tumor cells, and proved effective in controlling hormonal hypersecretion and inhibiting tumor growth, improving progression-free survival and overall survival of these patients. Aim of the present review is to investigate any differences by gender in efficacy and safety of SSTS-targeted therapies, that represent the mainstay treatment of neuroendocrine tumors, as they emerge from studies of varying design and intent. Although preclinical studies have provided evidence in favor of differences by gender in tumor expression of SSTR, as well as of the role of sex hormones and related receptors in modulating SSTRs expression and function, the clinical studies conducted so far have not shown substantial differences between males and females in either efficacy or toxicity of SSTR-targeted therapies, even if with sometimes inconsistent results. Moreover, in most studies gender was not a predictor of response to treatment. Studies specifically designed to address this issue are needed to develop gender-specific therapeutic algorithms, improving patients' prognosis and quality of life.
2023
gender; neuroendocrine neoplasms; prrt; somatostatin analogues (ssa); somatostatin receptors (sstr); therapy
01 Pubblicazione su rivista::01a Articolo in rivista
Efficacy and tolerability of somatostatin analogues according to gender in patients with neuroendocrine tumors / Ruggeri, Rosaria M; Aini, Irene; Gay, Stefano; Grossrubatscher, Erika Maria; Mancini, Camilla; Tarsitano, Maria Grazia; Zamponi, Virginia; Isidori, Andrea M; Colao, Annamaria; Faggiano, Antongiulio. - In: REVIEWS IN ENDOCRINE & METABOLIC DISORDERS. - ISSN 1389-9155. - (2023), pp. 1-16. [10.1007/s11154-023-09858-6]
File allegati a questo prodotto
File Dimensione Formato  
Ruggeri_Efficacy-and-tolerability_2023.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.24 MB
Formato Adobe PDF
1.24 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1695375
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact